Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

The new ESC Guidelines for Management of Elevated Blood Pressure and Hypertension were presented at the ESC Congress in London and reinforce the safety and effectiveness of renal denervation, recommending its consideration as a treatment option to improve uncontrolled hypertension.

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) have endorsed the updated recommendations for the management of hypertension by the European Society of Cardiology (ESC), which were presented at the ESC Congress on Friday, August 30, 2024.

The new guidelines, “2024 ESC Guidelines for the management of elevated blood pressure and hypertension,” have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

Hypertension, or high blood pressure, affects more than one billion people worldwide. It is known as the “silent killer” because many people do not know they have it and, over time, it can lead to serious health issues. About three-fourths of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking multiple medications. Recor’s Paradise™ Ultrasound Renal Denervation (uRDN) system is a first-of-its-kind ultrasound-based renal denervation technology designed to lower blood pressure by denervating overactive sympathetic nerves surrounding the renal arteries in patients whose hypertension is not controlled by medications alone.

“This presented guidance from the ESC Congress 2024 is a big step forward for patients who require a safe and effective option to control hypertension when lifestyle changes and medications are unsuccessful. The recommendation is based on the demonstrated efficacy and safety of renal denervation in randomized sham-controlled trials, and I am very pleased that RDN is now recommended in the ESC Guidelines as a treatment option for refractory and non-adherent patients,” commented Prof. Dr. Michael Böhm, Cardiologist and Clinic Director of Internal Medicine III, Saarland University Hospital in Homburg. “As presented at the congress the ESC guidelines recommend that renal denervation be performed in medium-to-high volume centers after multidisciplinary assessment and with a shared risk benefit discussion with the patient. It is now up to us to implement these guidelines in everyday clinical practice and provide patients with the services they need.”

Recor Medical has completed three global, independently powered, sham-controlled randomized clinical trials of the Paradise uRDN system in more than 500 patients with uncontrolled hypertension. The RADIANCE-HTN SOLO, RADIANCE-HTN TRIO and RADIANCE II clinical studies met their prespecified primary efficacy endpoints of blood pressure reduction, with positive safety outcomes. The Paradise system received CE mark in 2012, and Recor has been actively working with the European cardiology community to bring ultrasound RDN therapy to patients in the region. The growing support of societies like the ESC provides further momentum for the ongoing adoption of Recor’s hypertension therapy.

“We are delighted that the ESC guidelines recommend the consideration of renal denervation as an effective option to treat uncontrolled hypertension,” said Recor President and CEO, Lara Barghout. “The urgent global need to address the burden of uncontrolled hypertension remains, and we’re committed to revolutionizing the way hypertension is treated by bringing the benefits of Paradise ultrasound RDN to patients who need it.”

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."